ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

Science

Volumn 335, Issue 6075, 2012, Pages 1503-1506

  Cramer, Paige E ^a   Cirrito, John R ^b   Wesson, Daniel W ^a,c   Lee, C Y Daniel ^a   Karlo, J Colleen ^a   Zinn, Adriana E ^a   Casali, Brad T ^a   Restivo, Jessica L ^b   Goebel, Whitney D ^b   James, Michael J ^d   Brunden, Kurt R ^d   Wilson, Donald A ^c   Landreth, Gary E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BEXAROTENE; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR;

BIOCHEMISTRY; BRAIN; COGNITION; DISEASE TREATMENT; GENE EXPRESSION; MENTAL HEALTH; NERVOUS SYSTEM DISORDER; PHYSIOLOGY; PROTEIN; RODENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANOSMIA; ARTICLE; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84862777666     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1217697     Document Type: Article

References (25)

1. H. W. Querfurth, F. M. LaFerla, N. Engl. J. Med. 362, 329 (2010).
2. K. G. Mawuenyega et al., Science 330, 1774 (2010).
3. J. J. Palop, L. Mucke, Nat. Neurosci. 13, 812 (2010).
4. A. D. Roses, A. M. Saunders, Curr. Opin. Biotechnol. 5, 663 (1994).
5. J. J. Donkin et al., J. Biol. Chem. 285, 34144 (2010).
6. Q. Jiang et al., Neuron 58, 681 (2008).
7. A. Chawla et al., Mol. Cell 7, 161 (2001).
8. P. Lefebvre, Y. Benomar, B. Staels, Trends Endocrinol. Metab. 21, 676 (2010).
9. J. I. Odegaard, A. Chawla, Annu. Rev. Pathol. 6, 275 (2011).
10. S. Mandrekar-Colucci, G. E. Landreth, Expert Opin. Ther. Targets 15, 1085 (2011).
11. FDA, www.accessdata.fda.gov/drugsatfda-docs/nda/99/21055-Targretin.cfm (1999).
12. L. T. Farol, K. B. Hymes, Expert Rev. Anticancer Ther. 4, 180 (2004).
13. J. R. Cirrito et al., J. Neurosci. 23, 8844 (2003).
14. R. Radde et al., EMBO Rep. 7, 940 (2006).
15. D. W. Wesson, D. A. Wilson, Behav. Brain Res. 216, 408 (2011).
16. C. Murphy, Physiol. Behav. 66, 177 (1999).
17. D. W. Wesson, E. Levy, R. A. Nixon, D. A. Wilson, J. Neurosci. 30, 505 (2010).
18. D. W. Wesson et al., J. Neurosci. 31, 15962 (2011).
19. N. Kopell, G. B. Ermentrout, M. A. Whittington, R. D. Traub, Proc. Natl. Acad. Sci. U.S.A. 97, 1867 (2000).
20. H. Fukumoto et al., J. Neurosci. 30, 11157 (2010).
21. T. A. Comery et al., J. Neurosci. 25, 8898 (2005).
22. J. C. Dodart et al., Nat. Neurosci. 5, 452 (2002).
23. L. Jones et al., PLoS ONE 5, e13950 (2010).
24. P. Hollingworth et al., Nat. Genet. 43, 429 (2011).
25. A. C. Naj et al., Nat. Genet. 43, 436 (2011).